Antipyrine kinetics were measured on saliva in eight anaesthetists during a period when they were giving general anaesthetics and a period when they were working exclusively in intensive care. During the anaesthesia period there was a reduction in antipyrine half-life and the clearance of antipyrine increased. Analysis of the data in groups failed to detect these changes because of the wide variation in metabolism between subjects. Exposure to anaesthetic agents under non-scavenging operating theatre conditions appears to enhance hepatic metabolism.
References
1.
BrownB. R., and SagalynA. M. (1974): “Hepatic microsomal enzyme induction by inhalation anaesthetics: mechanism in the rat”, Anesthesiology, 40, 152–161.
2.
BrownB. R. (1976): “Clinical significance of the biotransformation of inhalation anesthetics”, Southern Med. J., 69, 554–556.
3.
BermanM. L., GreenO. C., CalverleyR. K., SmithN. T., and EgerE. I. (1976): “Enzyme induction by enflurane in man”, Anesthesiology, 44, 496–500.
4.
BranchR. A., ShandD. G., WilkinsonG. R., and NiesA. S. (1974): “Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey”, J. Clin. Invest., 53, 1101–1107.
5.
CascorbiH. F., BlakeD. A., and HelrichM. (1970): “Differences in the biotransformation of halo-thane in man”, Anesthesiology, 32, 119–123.
6.
CascorbiH. F., VesellE. S., BlakeD. A., and HelrichM. (1971): “Genetic and environmental influence on halothane metabolism in twins”, Clin. Pharmac. Ther., 12, 50–55.
7.
CookT. L., BeppuW. J., HittB. A., KosekJ. C., and MazzeR. I. (1975): “A comparison of renal effects and metabolism of sevoflurane and methoxyflurane in enzyme induced rats”, Anesth. Analg. Curr. Res., 54, 829–835.
8.
CousinsM. J., GreensteinL. R., HittB. A., and MazzeR. I. (1976): “Metabolism and renal effects of enflurane in man”, Anesthesiology, 44, 44–53.
9.
HarmanA. W., PenhallR. K., PriestlyB. G., FrewinD. B., PhillipsP. J., and ClarksonA. R. (1977): “Salivary antipyrine kinetics in hepatic and renal disease and in patients on anticonvulsant therapy”, Aust. N.Z. J. Med., 7, 385–390.
10.
HartP., FarrellG. C., CooksleyW. G. E., and PowellL. W. (1976): “Enhanced drug metabolism in cigarette smokers”, Brit. Med. J., 2, 147–149.
11.
LindeH. W., and BermanM. L. (1971): “Non-specific stimulation of drug metabolizing enzymes by inhalation anesthetic agents”, Anesth. Analg. Curr. Res., 50, 656–665.
12.
MazzeR. I., HittB. A., and CousinsM. J. (1974): “Effect of enzyme induction with phenobarbitol on the in vivo and in vitro defluorination of isoflurane and methoxyflurane”, J. Pharmac. Exp. Ther., 190, 523–529.
13.
StevensonI. H. (1977): “Factors influencing antipyrine elimination”, Brit. J. Clin. Pharmac, 4, 261–265.
14.
VesellE. S., and PageJ. (1968): “Genetic control of drug levels in man: antipyrine”, Science, 161, 72–73.
15.
VesellE. S., PassanantiG. T., GlenwrightP. A., and DvorchikB. H. (1975): “Studies on the disposition of antipyrine, aminopyrine and phenacetin using plasma, saliva and urine”, Clin. Pharmac. Ther., 18, 259–272.
16.
WelchR. M., DeAngelisR. L., WingfieldM., and FarmerT. W. (1975): “Elimination of antipyrine from saliva as a measure of metabolism in man”, Clin. Pharmac. Ther., 18, 249–258.
17.
WoodM., O'MalleyK., and StevensonI. H. (1974): “Drug metabolizing ability in operating theatre personnel”, Brit. J. Anaesth., 46, 726–728.
